ADMA
Price
$14.36
Change
-$0.20 (-1.37%)
Updated
Oct 17 closing price
Capitalization
3.43B
17 days until earnings call
Intraday Buy/Sell Signals
NVCT
Price
$6.17
Change
+$0.08 (+1.31%)
Updated
Oct 17 closing price
Capitalization
157.07M
23 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ADMA vs NVCT

Header iconADMA vs NVCT Comparison
Open Charts ADMA vs NVCTBanner chart's image
ADMA Biologics
Price$14.36
Change-$0.20 (-1.37%)
Volume$2.11M
Capitalization3.43B
Nuvectis Pharma
Price$6.17
Change+$0.08 (+1.31%)
Volume$62.11K
Capitalization157.07M
ADMA vs NVCT Comparison Chart in %
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADMA vs. NVCT commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a Hold and NVCT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (ADMA: $14.36 vs. NVCT: $6.17)
Brand notoriety: ADMA and NVCT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADMA: 67% vs. NVCT: 80%
Market capitalization -- ADMA: $3.43B vs. NVCT: $157.07M
ADMA [@Biotechnology] is valued at $3.43B. NVCT’s [@Biotechnology] market capitalization is $157.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADMA’s FA Score shows that 1 FA rating(s) are green whileNVCT’s FA Score has 0 green FA rating(s).

  • ADMA’s FA Score: 1 green, 4 red.
  • NVCT’s FA Score: 0 green, 5 red.
According to our system of comparison, ADMA is a better buy in the long-term than NVCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADMA’s TA Score shows that 5 TA indicator(s) are bullish while NVCT’s TA Score has 3 bullish TA indicator(s).

  • ADMA’s TA Score: 5 bullish, 3 bearish.
  • NVCT’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, ADMA is a better buy in the short-term than NVCT.

Price Growth

ADMA (@Biotechnology) experienced а -1.24% price change this week, while NVCT (@Biotechnology) price change was +3.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

ADMA is expected to report earnings on Nov 05, 2025.

NVCT is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ADMA($3.43B) has a higher market cap than NVCT($157M). NVCT YTD gains are higher at: 14.048 vs. ADMA (-16.268). ADMA has higher annual earnings (EBITDA): 163M vs. NVCT (-22.97M). ADMA has more cash in the bank: 90.3M vs. NVCT (26.8M). ADMA has higher revenues than NVCT: ADMA (474M) vs NVCT (0).
ADMANVCTADMA / NVCT
Capitalization3.43B157M2,183%
EBITDA163M-22.97M-710%
Gain YTD-16.26814.048-116%
P/E Ratio16.89N/A-
Revenue474M0-
Total Cash90.3M26.8M337%
Total Debt83.8MN/A-
FUNDAMENTALS RATINGS
ADMA: Fundamental Ratings
ADMA
OUTLOOK RATING
1..100
15
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
PROFIT vs RISK RATING
1..100
40
SMR RATING
1..100
16
PRICE GROWTH RATING
1..100
83
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ADMANVCT
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 11 days ago
87%
Declines
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IGFAX9.390.08
+0.86%
VY® Morgan Stanley Global Franchise A
MLVHX20.110.16
+0.80%
MFS Low Volatility Equity I
HCAIX116.470.40
+0.34%
Harbor Capital Appreciation Inv
MSTFX12.380.04
+0.32%
Morningstar International Equity
FIVMX13.51-0.05
-0.37%
Fidelity Advisor International Value A

ADMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with VRDN. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then VRDN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
-1.37%
VRDN - ADMA
40%
Loosely correlated
+5.22%
IDYA - ADMA
39%
Loosely correlated
+5.67%
NUVL - ADMA
39%
Loosely correlated
+2.32%
RVMD - ADMA
39%
Loosely correlated
+8.90%
CPRX - ADMA
38%
Loosely correlated
+0.10%
More

NVCT and

Correlation & Price change

A.I.dvisor tells us that NVCT and PDSB have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NVCT and PDSB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVCT
1D Price
Change %
NVCT100%
+1.31%
PDSB - NVCT
32%
Poorly correlated
-2.04%
ADMA - NVCT
32%
Poorly correlated
-1.37%
SGMT - NVCT
28%
Poorly correlated
-2.52%
AVBP - NVCT
26%
Poorly correlated
-0.59%
ZLAB - NVCT
26%
Poorly correlated
-1.91%
More